--- name: interpreting-cardiac-catheterization language: en description: Structures cath lab report interpretation with hemodynamics, angiographic findings, and intervention documentation. Use when reviewing cath reports, documenting PCI procedures, or interpreting hemodynamic data. tags: - analysis - cardiology metadata: author: casemark practice_areas: - Cardiology - Interventional Cardiology - Electrophysiology document_types: - Interpretation Report skill_modes: - Analysis - Interpretation --- # Interpreting Cardiac Catheterization Structures cath lab report interpretation with hemodynamics, angiographic findings, and intervention documentation. ## Why This Skill Exists Cardiac catheterization remains the gold standard for coronary artery disease assessment and the definitive hemodynamic evaluation tool. Misinterpretation of coronary angiography — underestimating a left main lesion, failing to recognize FFR-significant stenosis, or missing anomalous coronary anatomy — can lead to inappropriate revascularization decisions or lethal delays. Similarly, hemodynamic data from right and left heart catheterization drives critical decisions in valvular disease, pulmonary hypertension, cardiomyopathy, and shock management. The SCAI (Society for Cardiovascular Angiography and Interventions) and ACC mandate structured reporting of catheterization findings. This skill enforces systematic documentation of hemodynamics, coronary anatomy, lesion severity, intervention details, and complications. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. What was the indication for catheterization — ACS, stable angina, preoperative, valvular evaluation, hemodynamic assessment, or cardiomyopathy workup? (default: "Indication not specified") 2. Was this a diagnostic catheterization only, or was PCI performed? (default: "Diagnostic only") 3. Was right heart catheterization (RHC) performed in addition to left heart? (default: "LHC only") 4. What is the patient's baseline renal function (Cr, eGFR)? (default: "Not provided — flag contrast nephropathy risk") 5. Were any prior catheterizations performed? (default: "No prior cath available") 6. Are prior non-invasive stress test or imaging results available? (default: "Not provided") 7. What vascular access was used — radial, femoral, or other? (default: "Not specified") ### Documents to Request - Full catheterization report with angiographic images - Hemodynamic tracings (pressure waveforms) - Prior catheterization reports for comparison - Non-invasive testing results (stress echo, nuclear, CCTA) - Echocardiogram (for valve correlation) - Current medication list (antiplatelet, anticoagulant) - Labs: BMP, CBC, coagulation studies, troponin trend if ACS --- ## Step 1: Hemodynamic Data Interpretation **Normal Resting Hemodynamic Values:** | Parameter | Normal Range | |-----------|-------------| | RA mean | 0–8 mmHg | | RV systolic/diastolic | 15–30 / 0–8 mmHg | | PA systolic/diastolic/mean | 15–30 / 4–12 / 9–18 mmHg | | PCWP (mean) | 4–12 mmHg | | LV systolic/EDP | 100–140 / 4–12 mmHg | | Aortic systolic/diastolic/mean | 100–140 / 60–90 / 70–105 mmHg | | Cardiac output (Fick) | 4.0–8.0 L/min | | Cardiac index | 2.5–4.0 L/min/m² | | SVR | 800–1200 dynes·s/cm⁵ | | PVR | < 3 Wood units (< 240 dynes·s/cm⁵) | **Key Hemodynamic Calculations:** - Cardiac output (Fick) = VO₂ / (1.36 × Hgb × 10 × [SaO₂ − SvO₂]) - SVR = (MAP − RAP) × 80 / CO - PVR = (mPAP − PCWP) × 80 / CO - Valve area (Gorlin formula): AVA = CO / (44.3 × SEP × HR × √mean gradient) **Hemodynamic Pattern Recognition:** | Pattern | RA | PCWP | CO/CI | Diagnosis | |---------|----|----- |-------|-----------| | ↑ RA, ↑ PCWP, ↓ CO | High | High | Low | Cardiogenic shock | | ↑ RA, normal PCWP, ↓ CO | High | Normal | Low | RV failure / PE / tamponade | | Equalization of diastolic pressures | RA ≈ RVDP ≈ PADP ≈ PCWP | — | Low | Constrictive pericarditis or tamponade | | ↑ PCWP with V waves | Normal-high | V wave > 2× mean PCWP | Variable | Severe mitral regurgitation | --- ## Step 2: Coronary Angiography Interpretation **Standard Coronary Anatomy Reporting:** - Left main (LM): length, caliber, disease - Left anterior descending (LAD): proximal, mid, distal segments; diagonal branches (D1, D2) - Left circumflex (LCx): proximal, distal; obtuse marginal branches (OM1, OM2) - Right coronary artery (RCA): proximal, mid, distal; posterior descending (PDA), posterolateral (PLV) - Dominance: right-dominant (85%), left-dominant (8%), co-dominant (7%) **Lesion Severity Classification:** | Severity | % Stenosis | Clinical Significance | |----------|-----------|----------------------| | Mild | 1–49% | Non-obstructive | | Moderate | 50–69% | Borderline — consider FFR/iFR | | Severe | 70–99% | Obstructive — revascularization candidate | | Total occlusion | 100% | CTO — assess collateral supply | | Left main | ≥ 50% | Significant by definition | **Physiologic Assessment:** - FFR (fractional flow reserve): ≤ 0.80 = hemodynamically significant - iFR (instantaneous wave-free ratio): ≤ 0.89 = significant - IVUS/OCT: used for plaque characterization, stent optimization, left main assessment **Lesion Morphology (ACC/AHA Classification):** - Type A: discrete (< 10 mm), concentric, non-calcified → high PCI success - Type B1: tubular (10–20 mm), eccentric, moderate calcification → moderate risk - Type B2: two or more Type B features → higher risk - Type C: diffuse (> 20 mm), total occlusion, degenerated graft → highest risk --- ## Step 3: PCI Documentation (If Intervention Performed) Document each intervention with: 1. Target vessel and segment 2. Lesion characteristics (length, calcification, bifurcation involvement) 3. Pre-intervention stenosis percentage 4. Guidewire and catheter used 5. Pre-dilation details (balloon size, pressure, result) 6. Stent deployed (DES type, dimensions, deployment pressure) 7. Post-dilation (if performed) 8. Final angiographic result (residual stenosis, TIMI flow grade) 9. Complications (dissection, perforation, no-reflow, side branch loss) **TIMI Flow Grading:** | Grade | Definition | |-------|-----------| | 0 | No perfusion — complete occlusion | | 1 | Penetration without perfusion — contrast passes but fails to opacify the distal bed | | 2 | Partial perfusion — distal bed opacifies but with delayed filling or clearance | | 3 | Complete perfusion — normal filling and clearance | --- ## Step 4: Ventriculography and Additional Findings **LV Function by Ventriculography:** - Qualitative: normal, mild/moderate/severe hypokinesis, akinesis, dyskinesis - LVEF estimation from RAO 30° projection - Wall motion abnormalities mapped to coronary territories **Additional Assessments:** - Aortography: aortic regurgitation grading (1+ to 4+), aortic root dimensions - Shunt assessment: step-up in O₂ saturation (Qp:Qs > 1.5 = significant L→R shunt) - Transplant evaluation: right heart hemodynamics, PVR calculation, vasoreactivity testing --- ## Step 5: Post-Procedure Assessment and Complications **Immediate Post-Cath Monitoring:** - Access site: hematoma, retroperitoneal bleed, pseudoaneurysm, AV fistula - Renal: contrast-induced nephropathy risk (hydrate; check Cr at 48–72 hours) - Vascular: limb ischemia if femoral approach, radial artery occlusion - Cardiac: post-PCI chest pain, stent thrombosis, coronary dissection **Dual Antiplatelet Therapy (DAPT) Post-PCI:** - After DES: aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) - ACS: minimum 12 months DAPT - Stable CAD: minimum 6 months DAPT (3 months in high bleeding risk) - Triple therapy (DOAC + DAPT) if concurrent AF: minimize duration; de-escalate to DOAC + single antiplatelet --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. Are all hemodynamic values documented with normal references? 2. Is every coronary artery segment reported with dominance stated? 3. For PCI: is the lesion, device, and result fully documented with TIMI flow? 4. Are complications assessed and documented or their absence noted? 5. Is the post-procedure antiplatelet plan specified with duration? --- ## Quality Audit - [ ] Indication for catheterization clearly stated - [ ] Vascular access site and technique documented - [ ] Complete hemodynamic data with normal reference ranges - [ ] Coronary dominance identified - [ ] All coronary arteries and major branches described - [ ] Lesion severity quantified (%) for each stenosis - [ ] FFR/iFR reported for intermediate lesions (50–70%) - [ ] PCI details complete: lesion, equipment, stent specs, final result - [ ] TIMI flow grade documented pre- and post-intervention - [ ] LV function assessed (by ventriculography or prior echo) - [ ] Complications listed or "no complications" explicitly stated - [ ] Contrast volume documented (nephropathy risk) - [ ] Post-procedure medication plan (DAPT) documented - [ ] Comparison with prior catheterization if available --- ## Guidelines 1. Report coronary dominance in every catheterization interpretation — it affects the clinical significance of RCA vs. LCx lesions. 2. Intermediate stenoses (50–69%) should trigger documentation of whether physiologic assessment (FFR/iFR) was performed or planned. 3. For left main disease ≥ 50%, always document referral to Heart Team discussion for CABG vs. PCI per ACC/AHA guidelines. 4. Hemodynamic waveforms should be correlated with clinical context — giant V waves on PCWP tracing must be reported and correlated with MR severity on echo. 5. Contrast volume should be documented and kept below 3–4× eGFR to minimize nephropathy risk. 6. When CTO is identified, document the presence and grade of collateral supply (Rentrop classification). 7. Post-PCI DAPT duration must account for bleeding risk, ischemic risk, and concurrent anticoagulation needs — document the rationale for chosen duration. --- Source attribution: CaseMark Original project: https://github.com/CaseMark/skills/blob/449269ec49b6a8f1b4614cea52aa44b2a76e4e94/skills/med/interpreting-cardiac-catheterization/SKILL.md License: Apache-2.0 License information: https://www.apache.org/licenses/LICENSE-2.0 Original upstream instructions; downloaded from Mega AI Hub. ## Upstream license notice Apache License Version 2.0, January 2004 http://www.apache.org/licenses/ TERMS AND CONDITIONS FOR USE, REPRODUCTION, AND DISTRIBUTION 1. Definitions. "License" shall mean the terms and conditions for use, reproduction, and distribution as defined by Sections 1 through 9 of this document. "Licensor" shall mean the copyright owner or entity authorized by the copyright owner that is granting the License. "Legal Entity" shall mean the union of the acting entity and all other entities that control, are controlled by, or are under common control with that entity. For the purposes of this definition, "control" means (i) the power, direct or indirect, to cause the direction or management of such entity, whether by contract or otherwise, or (ii) ownership of fifty percent (50%) or more of the outstanding shares, or (iii) beneficial ownership of such entity. "You" (or "Your") shall mean an individual or Legal Entity exercising permissions granted by this License. "Source" form shall mean the preferred form for making modifications, including but not limited to software source code, documentation source, and configuration files. "Object" form shall mean any form resulting from mechanical transformation or translation of a Source form, including but not limited to compiled object code, generated documentation, and conversions to other media types. "Work" shall mean the work of authorship, whether in Source or Object form, made available under the License, as indicated by a copyright notice that is included in or attached to the work (an example is provided in the Appendix below). "Derivative Works" shall mean any work, whether in Source or Object form, that is based on (or derived from) the Work and for which the editorial revisions, annotations, elaborations, or other modifications represent, as a whole, an original work of authorship. For the purposes of this License, Derivative Works shall not include works that remain separable from, or merely link (or bind by name) to the interfaces of, the Work and Derivative Works thereof. "Contribution" shall mean any work of authorship, including the original version of the Work and any modifications or additions to that Work or Derivative Works thereof, that is intentionally submitted to the Licensor for inclusion in the Work by the copyright owner or by an individual or Legal Entity authorized to submit on behalf of the copyright owner. For the purposes of this definition, "submitted" means any form of electronic, verbal, or written communication sent to the Licensor or its representatives, including but not limited to communication on electronic mailing lists, source code control systems, and issue tracking systems that are managed by, or on behalf of, the Licensor for the purpose of discussing and improving the Work, but excluding communication that is conspicuously marked or otherwise designated in writing by the copyright owner as "Not a Contribution." "Contributor" shall mean Licensor and any individual or Legal Entity on behalf of whom a Contribution has been received by the Licensor and subsequently incorporated within the Work. 2. Grant of Copyright License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable copyright license to reproduce, prepare Derivative Works of, publicly display, publicly perform, sublicense, and distribute the Work and such Derivative Works in Source or Object form. 3. Grant of Patent License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable (except as stated in this section) patent license to make, have made, use, offer to sell, sell, import, and otherwise transfer the Work, where such license applies only to those patent claims licensable by such Contributor that are necessarily infringed by their Contribution(s) alone or by combination of their Contribution(s) with the Work to which such Contribution(s) was submitted. If You institute patent litigation against any entity (including a cross-claim or counterclaim in a lawsuit) alleging that the Work or a Contribution incorporated within the Work constitutes direct or contributory patent infringement, then any patent licenses granted to You under this License for that Work shall terminate as of the date such litigation is filed. 4. Redistribution. You may reproduce and distribute copies of the Work or Derivative Works thereof in any medium, with or without modifications, and in Source or Object form, provided that You meet the following conditions: (a) You must give any other recipients of the Work or Derivative Works a copy of this License; and (b) You must cause any modified files to carry prominent notices stating that You changed the files; and (c) You must retain, in the Source form of any Derivative Works that You distribute, all copyright, patent, trademark, and attribution notices from the Source form of the Work, excluding those notices that do not pertain to any part of the Derivative Works; and (d) If the Work includes a "NOTICE" text file as part of its distribution, then any Derivative Works that You distribute must include a readable copy of the attribution notices contained within such NOTICE file, excluding any notices that do not pertain to any part of the Derivative Works, in at least one of the following places: within a NOTICE text file distributed as part of the Derivative Works; within the Source form or documentation, if provided along with the Derivative Works; or, within a display generated by the Derivative Works, if and wherever such third-party notices normally appear. The contents of the NOTICE file are for informational purposes only and do not modify the License. You may add Your own attribution notices within Derivative Works that You distribute, alongside or as an addendum to the NOTICE text from the Work, provided that such additional attribution notices cannot be construed as modifying the License. You may add Your own copyright statement to Your modifications and may provide additional or different license terms and conditions for use, reproduction, or distribution of Your modifications, or for any such Derivative Works as a whole, provided Your use, reproduction, and distribution of the Work otherwise complies with the conditions stated in this License. 5. Submission of Contributions. Unless You explicitly state otherwise, any Contribution intentionally submitted for inclusion in the Work by You to the Licensor shall be under the terms and conditions of this License, without any additional terms or conditions. Notwithstanding the above, nothing herein shall supersede or modify the terms of any separate license agreement you may have executed with Licensor regarding such Contributions. 6. Trademarks. This License does not grant permission to use the trade names, trademarks, service marks, or product names of the Licensor, except as required for reasonable and customary use in describing the origin of the Work and reproducing the content of the NOTICE file. 7. Disclaimer of Warranty. Unless required by applicable law or agreed to in writing, Licensor provides the Work (and each Contributor provides its Contributions) on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied, including, without limitation, any warranties or conditions of TITLE, NON-INFRINGEMENT, MERCHANTABILITY, or FITNESS FOR A PARTICULAR PURPOSE. You are solely responsible for determining the appropriateness of using or redistributing the Work and assume any risks associated with Your exercise of permissions under this License. 8. Limitation of Liability. In no event and under no legal theory, whether in tort (including negligence), contract, or otherwise, unless required by applicable law (such as deliberate and grossly negligent acts) or agreed to in writing, shall any Contributor be liable to You for damages, including any direct, indirect, special, incidental, or consequential damages of any character arising as a result of this License or out of the use or inability to use the Work (including but not limited to damages for loss of goodwill, work stoppage, computer failure or malfunction, or any and all other commercial damages or losses), even if such Contributor has been advised of the possibility of such damages. 9. Accepting Warranty or Additional Liability. While redistributing the Work or Derivative Works thereof, You may choose to offer, and charge a fee for, acceptance of support, warranty, indemnity, or other liability obligations and/or rights consistent with this License. However, in accepting such obligations, You may act only on Your own behalf and on Your sole responsibility, not on behalf of any other Contributor, and only if You agree to indemnify, defend, and hold each Contributor harmless for any liability incurred by, or claims asserted against, such Contributor by reason of your accepting any such warranty or additional liability. END OF TERMS AND CONDITIONS Copyright 2025 CaseMark, Inc. Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License. You may obtain a copy of the License at http://www.apache.org/licenses/LICENSE-2.0 Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License. # Mega AI Hub resource metadata Creator / publisher: CaseMark Original project: https://github.com/CaseMark/skills/blob/449269ec49b6a8f1b4614cea52aa44b2a76e4e94/skills/med/interpreting-cardiac-catheterization/SKILL.md Attribution basis: Source repository record Fields of work: Healthcare & Life Sciences Roles: Clinical Research, Health Informatics, Medical Writer Specialties: Specialty not specified Tools: Tool not specified Country applicability: Country not specified Classification basis: Source catalog labels Instruction SHA-256: 4a3b570901f4b45d5453a8a2446b96dafb923f49992708f494347c29d26d9e74